Editas Medicine will eliminate about 180 roles after failing to find a commercial partner for an experimental sickle cell ...

Pfizer touts Ibrance’s status as a standard of care in HR-positive, HER2-negative metastatic breast cancer. Now the company ...

ICER reports $800M+ annual US cost increase from 5 drugs (Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz) with 2023 price ...

Former Padlock shareholders sue Bristol Myers Squibb over alleged unpaid milestone payments for antibody BMS-986454, claiming ...

Columvi combo in DLBCL, while AnaptysBio's ANB032 fails in atopic dermatitis. Essential Pharma gets €1.2B financing deal.

Eli Lilly partners with telehealth company Ro to distribute discounted Zepbound vials at $399/month, while competitor Novo ...

Demis Hassabis has no interest in a laboratory. The Nobel Prize-winning artificial intelligence pioneer is betting big on ...

End­points News has once again reached out to a lengthy ros­ter of biotech ex­ecs to take their pulse on what’s ahead for the ...

Keros Therapeutics halts two dosing arms of cibotercept Phase 2 trial due to pericardial effusion safety concerns; continues ...

Illumina exec Vik Vaz as CEO to advance biological detection tech for drug research. The company uses what it calls ...

Corcept Therapeutics' dazucorilant fails Phase 2 ALS trial after missing primary endpoint, following October's Cushing's ...

Lonza CEO Wolfgang Wienand plans to exit capsules/health ingredients market and restructure into three business units, with ...